Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, has announced it will release its financial results for the third quarter of 2024 after market close on Wednesday, October 23, 2024. The company will host a conference call to discuss these results and provide general corporate updates at 4:30 p.m. Eastern Time on the same day.
To participate in the conference call, U.S. callers can dial (844) 850-0543, while international callers should use (412) 317-5199. A telephone replay will be available until October 30, 2024, accessible by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S., using the replay access code #9473630. The call can also be accessed via webcast on Viking's website, with an archive available for 30 days.
Viking Therapeutics (NASDAQ: VKTX), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di nuove terapie per disturbi metabolici ed endocrini, ha annunciato che pubblicherà i suoi risultati finanziari per il terzo trimestre del 2024 dopo la chiusura del mercato il mercoledì 23 ottobre 2024. L'azienda organizzerà una conferenza telefonica per discutere di questi risultati e fornire aggiornamenti aziendali generali alle 16:30 ora orientale dello stesso giorno.
Per partecipare alla conferenza telefonica, i chiamanti statunitensi possono comporre (844) 850-0543, mentre i chiamanti internazionali dovrebbero usare (412) 317-5199. Una registrazione telefonica sarà disponibile fino al 30 ottobre 2024, accessibile componendo (877) 344-7529 dagli Stati Uniti o (412) 317-0088 dall'estero, utilizzando il codice di accesso alla registrazione #9473630. La chiamata può essere anche ascoltata tramite webcast sul sito web di Viking, con un archivio disponibile per 30 giorni.
Viking Therapeutics (NASDAQ: VKTX), una empresa biofarmacéutica en etapa clínica enfocada en el desarrollo de nuevas terapias para trastornos metabólicos y endocrinos, ha anunciado que publicará sus resultados financieros para el tercer trimestre de 2024 después del cierre del mercado el miércoles 23 de octubre de 2024. La empresa llevará a cabo una conferencia telefónica para discutir estos resultados y proporcionar actualizaciones corporativas generales a las 4:30 p.m. Hora del Este del mismo día.
Para participar en la conferencia telefónica, los llamantes de EE.UU. pueden marcar (844) 850-0543, mientras que los llamantes internacionales deben usar (412) 317-5199. Se dispondrá de una grabación telefónica hasta el 30 de octubre de 2024, accesible marcando (877) 344-7529 desde EE.UU. o (412) 317-0088 desde el extranjero, utilizando el código de acceso a la grabación #9473630. La llamada también se puede acceder a través de una retransmisión en el sitio web de Viking, con un archivo disponible durante 30 días.
Viking Therapeutics (NASDAQ: VKTX)는 대사 및 내분비 질환에 대한 새로운 치료법 개발에 중점을 둔 임상 단계의 생물 제약 회사로, 2024년 3분기 재무 결과를 2024년 10월 23일 수요일 시장 종료 후 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 오후 4시 30분에 이러한 결과를 논의하고 일반적인 기업 업데이트를 제공하기 위해 전화 회의를 개최합니다.
전화 회의에 참여하려면, 미국에서는 (844) 850-0543으로 전화하고, 국제 전화자는 (412) 317-5199로 전화해야 합니다. 전화 녹음은 2024년 10월 30일까지 이용 가능하며, 미국에서는 (877) 344-7529으로, 해외에서는 (412) 317-0088로 전화하여 #9473630 녹음 접근 코드를 사용하여 접근할 수 있습니다. 또한 Viking의 웹사이트를 통해 웹캐스트로 접속할 수 있으며, 30일 동안 아카이브가 제공됩니다.
Viking Therapeutics (NASDAQ: VKTX), une entreprise biopharmaceutique en phase clinique axée sur le développement de nouvelles thérapies pour les troubles métaboliques et endocriniens, a annoncé qu'elle publiera ses résultats financiers pour le troisième trimestre de 2024 après la clôture du marché le mercredi 23 octobre 2024. L'entreprise organisera une conférence téléphonique pour discuter de ces résultats et fournir des mises à jour générales sur l'entreprise à 16h30 heure de l'Est le même jour.
Pour participer à la conférence téléphonique, les appelants américains peuvent composer le (844) 850-0543, tandis que les appelants internationaux doivent utiliser le (412) 317-5199. Un enregistrement téléphonique sera disponible jusqu'au 30 octobre 2024, accessible en composant le (877) 344-7529 depuis les États-Unis ou le (412) 317-0088 depuis l'étranger, en utilisant le code d'accès à l'enregistrement #9473630. L'appel peut également être accessible via la diffusion Web sur le site internet de Viking, avec un archive disponible pendant 30 jours.
Viking Therapeutics (NASDAQ: VKTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger Therapien für Stoffwechsel- und endokrine Störungen spezialisiert hat, hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal 2024 nach Marktschluss am Mittwoch, den 23. Oktober 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um diese Ergebnisse zu diskutieren und allgemeine Unternehmensaktualisierungen bereitzustellen.
Um an der Telefonkonferenz teilzunehmen, können US-Anrufer (844) 850-0543 wählen, während internationale Anrufer (412) 317-5199 verwenden sollten. Eine Telefonaufzeichnung wird bis zum 30. Oktober 2024 verfügbar sein und ist erreichbar unter (877) 344-7529 aus den USA oder (412) 317-0088 aus dem Ausland, unter Verwendung des Zugangs Codes zur Aufnahme #9473630. Der Anruf kann auch per Webcast über die Website von Viking abgerufen werden, mit einem Archiv, das 30 Tage verfügbar ist.
- None.
- None.
Conference Call Scheduled for Wednesday, October 23 at 4:30 p.m. Eastern Time
The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, October 23, 2024. To participate on the conference call, please dial (844) 850-0543 from the
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders. In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). In a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viking-therapeutics-to-report-financial-results-for-third-quarter-2024-on-october-23-2024-302276687.html
SOURCE Viking Therapeutics, Inc.
FAQ
When will Viking Therapeutics (VKTX) report its Q3 2024 financial results?
What time is Viking Therapeutics' (VKTX) Q3 2024 earnings call scheduled for?
How can investors participate in Viking Therapeutics' (VKTX) Q3 2024 earnings call?
Until what date will the replay of Viking Therapeutics' (VKTX) Q3 2024 earnings call be available?
